Non-alcoholic Steatohepatitis (NASH) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

 Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD) where the liver becomes inflamed due to the accumulation of fat. NASH can progress to include scarring (fibrosis/cirrhosis), preventing the liver from functioning properly. Since the disease comes with few or no symptoms, it can go unnoticed for decades. As fibrosis worsens, cirrhosis develops and the liver becomes permanently damaged and is no longer able to work properly. Patients generally feel well in the early stages and only begin to have symptoms such as fatigue, weight loss, and weakness—once the disease is more advanced or cirrhosis develops. NASH is usually first suspected after elevations of liver enzymes in routine blood tests are found. A liver biopsy is needed to distinguish NASH from simple fatty liver.

·       NAFLD is highly prevalent in all continents, but the highest rates are reported from South America (31%) and the Middle East (32%), followed by Asia (27%), the USA (24%), and Europe (23%), whereas NAFLD is less common in Africa (14%).

·       NASH is now considered the second most common indication for liver transplantation in the USA after chronic hepatitis C and is still growing. The prevalence of NAFLD in the USA diagnosed by ultrasonography was estimated to be 24.13%. On the other hand, the prevalence of NAFLD was reported to be ~21.09%.

 

The competitive landscape of Non-alcoholic Steatohepatitis (NASH) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Non-alcoholic Steatohepatitis (NASH) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Non-alcoholic Steatohepatitis (NASH) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Non-alcoholic Steatohepatitis (NASH) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          ORMD-0801     Oramed, Ltd.     Phase 2

2          EDP-305           Enanta Pharmaceuticals            Phase 1

3          HepaStem        Promethera Biosciences            Phase 2

4          TERN-201         Terns Pharmaceuticals, Inc.       Phase 2

5          Namodenoson   Can-Fite BioPharma      Phase 2

6          BIO89-100        89bio, Inc.         Phase 2

7          VK2809 Viking Therapeutics, Inc.           Phase 2

8          AZD2693          AstraZeneca     Phase 1

9          BMS-986263     Bristol-Myers Squibb      Phase 2

10        BOS-580          Boston Pharmaceuticals Phase 2

Continued...